P21 Peptide: 5mg

Description

P21 is a tetrapeptide (davp sequence) derived from the c-terminal region of cntf (ciliary neurotrophic factor) that stimulates hippocampal neurogenesis — the formation of new neurons in the brain's primary memory and spatial navigation center — without triggering cntf's adverse off-target effects including severe weight loss, inflammation, cachexia, and broad systemic toxicity that limit cntf's research utility. p21 was developed specifically to isolate cntf's neuroprotective and neurogenic activity in a small, bbb-penetrant peptide. its mechanisms include stimulation of bdnf (brain-derived neurotrophic factor) expression, reduction of tau phosphorylation (a hallmark of alzheimer's pathology and tauopathies), inhibition of cntf's negative feedback through socs proteins, and direct promotion of neural progenitor cell differentiation in the hippocampal dentate gyrus. in alzheimer's disease animal models, p21 increased brain volume and hippocampal cell counts. in a head-to-head preclinical comparison, p21 outperformed cerebrolysin (a clinically used multi-peptide brain treatment mixture) on neurogenesis and cognitive outcome measures. p21 crosses the blood-brain barrier following subcutaneous injection. classified in the brain + repair category for its structural regenerative mechanism rather than acute mood or anxiolytic modulation. complementary to semax (bdnf pathway upregulation), dihexa (synaptogenesis via hgf/c-met), and pe-22-28 (mood-stabilizing neuroprotection). for research and educational purposes only.

Specifications

Dose Calculator